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A series of octameric quinoline oligoamide foldamers has been synthesized consisting
exclusively of monomers which display mono-, di-, tri- or tetra-ethylene glycol side-
chains. These oligomers adopt stable helical conformations. New Fmoc-acid monomer
precursors were ﬁrst developed. The microwave assisted solid-phase synthesis (SPS)
methodology for oligomer preparation is described, and it is demonstrated that small
adjustments in side-chain length translate into large differences in the solubility proﬁle of
the oligomers. The impact of such modiﬁcations on foldamer preparation, handedness
inversion kinetics and potential applications is also discussed.
© 2015 Academie des sciences. Published by Elsevier Masson SAS. This is an open access
article under the CCBY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).r é s u m é
Une serie de foldameres octameriques de quinolinecarboxamide composes de monomeres
portant des chaînes laterales mono-, di-, tri- ou tetraethylene glycol a ete synthetisee. Ces
composes adoptent des conformations repliees en helice stables. De nouveaux precurseurs
Fmoc-acide ont ete developpes au prealable. La synthese des precuseurs ainsi que la
preparation des sequences par synthese en phase solide (SPS) sont decrites. Il est
egalement demontre que des modiﬁcations mineures des chaînes laterales peuvent se
traduire par de grandes differences dans les proﬁls de solubilite des oligomeres. L'effet des
modiﬁcations des chaînes laterales sur la preparation des foldameres, sur la cinetique
d'inversion du sens d'helicite et sur les applications pratiques est aussi discute.
© 2015 Academie des sciences. Published by Elsevier Masson SAS. This is an open access
article under the CCBY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).CBMN (UMR 5248),
bert-Escarpit, 33607
).
ed by Elsevier Masson SAS.1. Introduction
The propensity of foldamers to fold and the properties
of their folded conformations directly express featuresThis is an open access article under the CC BY-NC-ND license (http://
Fig. 1. Isobutoxy, 3-aminopropoxy and triethylene glycol monomethyl ether
side-chains at position 4 of 8-amino-2-quinolinecarboxamide monomers.
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such, foldamer research critically depends on the devel-
opment of new desirable monomers and their easy incor-
poration into sequences. Thus, synthetic foldamers do not
face the same limitations as biopolymers which are based
on small ensembles of units (e.g. twenty amino acids for
proteins and four nucleobases for nucleic acids). In this
manuscript, we present the synthesis of quinoline amino
acids bearing oligoethylene glycol side-chains of various
lengths, their incorporation into oligomers via solid-phase
synthesis (SPS), and the determination of solubility prop-
erties endowed by these side-chains.
Aromatic amide foldamers are a growing class of olig-
omers that combine relatively easy synthetic access and
stable and predictable conformations [2]. The folding of
aromatic oligoamide foldamers arises from backbone ri-
gidity due to local electrostatic repulsions and hydrogen
bonds between amide function and adjacent units. The size
and orientation of substituents on each monomer deter-
mine the strand curvature, leading to linear [3], zig-zag [4],
or bent shapes [5], which eventually give rise to macro-
cycles [6], hydrogen-bonded duplexes [7], single [8] and
multiple [9] helices, and aromatic b-sheets [10]. In sheets
and helices, aromatic stacking, which may include elec-
trostatic and solvophobic components, brings about addi-
tional stabilization [11]. Thus aromatic oligoamide folding
depends primarily on main chain features, regardless of
side-chains which, with a few exceptions [9(a)] and unlike
in peptides and nucleotides, have little effect on the folded
conformations. Monomer development for aromatic amide
foldamers thus allows the consideration of main chain and
side-chain attributes in an orthogonal manner. Over the
years, a great variety of benzenic and heterocyclic building
blocks have been introduced that can be combined at will
[2,12].
For their part, side-chains determine the solubility. This
is not as trivial a question as it may appear as aromatic
oligoamides are inherently very poorly soluble molecules.
Nevertheless, appropriate substitution with groups
diverging from the folded structures allows solubility in all
kinds of media. Some side-chains like isobutoxy groups
provide high solubility in organic media and also favor
crystallogenesis [8,9,10,13]. Interest in controlling the sol-
ubility of aromatic oligoamides in a wide range of solvents
stems from the fact that folding has been shown to occur in
solvents as diverse as chloroform, toluene, dimethyl sulf-
oxide, methanol or water [11(b),14]. While folded confor-
mations do not depend much on the solvent, their stability
may be greatly inﬂuenced as illustrated by considerable
variations of the rate of helix handedness inversion in he-
lical foldamers [11(b)]. These variations may have practical
applications. For example, helix handedness induction by a
chiral residue may be effective in a solvent in which
handedness inversion is fast. Once handedness induction is
complete, the same molecule may be transferred into
another solvent in which the conformation is kinetically
inert [15].
Side-chains also determine the ability of the folded
structures to interact with other molecules, in particular
protein surfaces [14(b),16] and nucleic acids [17]. This
essential property has motivated the development ofaromatic amino acids bearing a wide range of side-chains
[14,16], and of microwave-assisted SPS methods to conve-
niently assemble them into varied sequences [18]. This al-
lows the rapid synthesis of oligomers where any position in
the sequence can be substituted for another, without the
laborious preparation and puriﬁcation of intermediates
required by a solution-phase strategy.
In this manuscript, we focus on oligoamide foldamers
derived from 8-amino-2-quinolinecarboxylic acid having
side-chains in position 4 (Fig. 1) [8,11,14,15,17,18(a)]. These
oligomers adopt very robust helical conformations that
have been used to construct organic soluble, isobutoxy-
substituted structures, of the size of small proteins [13].
The installation of an aminopropyl (i.e. ornithine-like) side-
chain endows oligomers with good water solubility, with
cell penetration properties [14(a),19], and with high afﬁnity
for G-quadruplex DNA [17]. Upon combining various pro-
teinogenic side-chains, interactions with protein surfaces
have been evidenced [14(b)]. In this context, we have been
interested in introducing oligoethylene glycol functional-
ized monomers. Such side-chains would ensure the solu-
bility of the same molecules in a wide range of solvents
allowing, for example, the locking of helix handedness in
water after inducing it in an organic solvent [15]; they may
also potentially reduce toxicity [20]; and avoid non-speciﬁc
interactions between foldamer surfaces and biomolecules
[21], discouraging any interference with interactions
involving designed recognition spots.
In a previous study [11(b)], we successfully incorporated
a triethylene glycol side-chain on a monomer and prepared
oligomers up to the octamer in solution (Fig. 1). These
oligomers were shown to be soluble in solvents ranging
from diethyl ether tomethanol/watermixtures. However, it
was noted that the arylealkyl ether linkage connecting the
side-chain to the quinoline position 4 was somewhat acid-
labile, most likely via a beta-elimination process, and that it
would not be compatible with the acidic conditions
required to cleave oligomers from the Wang resin after SPS
[18]. Here we present a strategy for the synthesis of Fmoc
protected quinoline monomers possessing oligoethylene
glycol (OEG) side-chains ranging from mono- to tetra-
ethylene glycol attached at the quinoline position 4 via an
acid-resistant thioether linkage. These monomers were
subsequently assembled in the SPS of four octameric se-
quences each consisting exclusively of one monomer type.
We demonstrate that these side-chains are compatible
with helix handedness separation by HPLC on a chiral
stationary phase, and also investigate the effect of OEG
side-chain length on the solubility proﬁle of each octameric
sequence.
Fig. 2. Crystal structure of monomer 4. Hydrogen atoms have been omitted
for clarity.
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2.1. Synthesis
Our strategy was to design a generic synthesis for Fmoc-
acid quinoline monomers ready for SPS which would allow
the attachment of potentially any length of OEG side-
chains. Thus, side-chains were introduced by the forma-
tion of the thioether linkage via aromatic nucleophilic
substitution of a 4-bromoquinoline intermediate [14(b)] by
the corresponding thiol (Scheme 1). Only the shortest side-
chain precursor (2-methoxyethanethiol) is commercially
available. Other precursors were prepared in three steps
from OEG monomethyl ethers which are commercially
available for a wide range of oligo- and poly-ethylene gly-
cols. Following previously reported methods [22], these
precursors were tosylated, subsequently substituted by
thiourea and hydrolyzed to yield the desired thiol products
in 24e64% yields over the three steps.
Aromatic nucleophilic substitution of methyl 8-nitro-4-
bromo-2-quinolinecarboxylate [14(b)] afforded 8-nitro 2-
ester monomer intermediates in good yields (54e78%).
These could be obtained with excellent purity due to their
high crystallinity, even for the tri- and tetra-ethylene glycol
chains. From there, the desired monomers (1e4) could be
obtained through saponiﬁcation of the methyl ester,
reduction of the nitro group by catalytic hydrogenation and
Fmoc protection of the amine.
Of these three steps, only the reduction step required
some optimization; H2/PdeC was found to be somewhat
sluggish, presumably due to gradual poisoning of the cata-
lyst by traces of thiol intermediates. This problemwas easily
overcome by using the more rapid NH4HCO2/PdeC system.
Fmoc monomers were therefore afforded in 30e50% overall
yields on 1 g scale syntheses from the bromoquinoline in-
termediate. Interestingly all the Fmoc monomers were
found to be amenable to crystallization. It was possible to
use this as an extra puriﬁcation step for achieving mono-
mers of high purity. Fig. 2 shows the crystal structure of the
tetraethylene glycol-functionalized monomer 4.Scheme 1. Synthesis of Fmoc quinoline buSPS of quinoline carboxamide oligomers is commonly
carried out on Wang resin and affords a free C-terminal
carboxylic acid function after resin cleavage [18]. However,
in order to afford oligomers which would be amenable to
puriﬁcation by both normal and reverse-phase HPLC,
recycling gel permeation chromatography (GPC), or even
ﬂash chromatography, we decided to avoid the carboxylic
acid function and to follow a strategy which would provide
a primary amide at the C-terminus. This was anticipated to
signiﬁcantly reduce oligomer polarity without causing
problems with solubility. Our initial attempts with SPS on
Rink amide resin [23] were unsuccessful due to an unex-
pected resistance to the normal acidic cleavage conditions
(95% TFA). We therefore utilized Sieber amide resin [24]
which has a higher degree of acid lability. The ﬁrst mono-
mer could be loaded onto the resin either using HBTU/HOBt
in DMF, or via the acid chloride, pre-formed by treatment of
monomer acid with the Ghosez reagent (1-chloro-N,N,2-
trimethyl-1-propenylamine) [25], in THF underilding blocks with OEG side-chains.
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carried out at room temperature using 20% v/v piperidine
in DMF and SPS continued in this fashion by coupling of the
pre-formed monomer acid chlorides using the microwave-
assisted methodology [18]. The sequence was terminated
by coupling the nitro acid intermediate of eachmonomer in
the same manner.
Thus, homomeric octamers 5e8were prepared from the
corresponding monomers 1e4 on a 16e32 mmol scale with
crude purities ranging from 80 to 86%. Each oligomer could
be puriﬁed by RP-HPLC, except for the monoethylene
glycol-functionalized compound 5, due to poor solubility in
water/acetonitrile mixtures. Instead, this was puriﬁed by
recycling GPC in chloroform (see Experimental section). The
tetraethylene glycol-functionalized octamer 8 was ﬁrst
puriﬁed by RP-HPLC, however it was clear by NMR and MS
analysis that even after chromatographic treatment, the
material also contained a nonameric sequence which could
not be separated from the desired octamer due to very
similar retention times on the C18 reverse-phase prepara-
tive column. Fortunately this nonameric by-product was
sufﬁciently different in size from the desired octamer that it
could be removed by recycling GPC. The insertion of an
additional monomer presumably reﬂects slightly too harsh
coupling conditions during one of the steps that may result
in partial Fmoc cleavage while some activated acid is still
present. To avoid this kind of side reaction and the subse-
quent difﬁcult puriﬁcation, it is recommended not to exceed
the reported heating temperature and coupling duration.
2.2. Solubility studies
We anticipated that one critical difference between the
four octamers synthesized would be their solubility
proﬁle. Previous experience with a triethylene glycol-
functionalized octamer similar to 7 had demonstrated
that this side-chain afforded solubility in a wide range ofScheme 2. SPS of OEG funcsolvents at concentrations sufﬁcient to allow the mea-
surement of circular dichroism [11(b)]. However, while
methanol/water mixtures containing up to 50% v/v water
were tolerated, this octamer was not soluble in pure water.
By increasing the side-chain length by one ethylene glycol
unit, we hoped to access this property with compound 8. In
addition, we aimed to investigate the solubility behavior of
octamers 5 and 6, which during their puriﬁcation had
shown themselves to bemore compatible with low polarity
organic solvents.
A quantitative assessment of the solubility of 5e8 in
eight typical solvents was carried out via UV absorbance
measurement. A saturated solution of the studied oligomer
was produced by adding excess solid material to a partic-
ular solvent, stirring and allowing a mixing time of 15 min
at 20 C. The mixture was then centrifuged at 6000 rpm for
5 min, or until a clear supernatant had been achieved as
assessed by light microscopy. An accurately measured
volume of the supernatant was then removed and evapo-
rated to dryness. The residue was dissolved in DMSO, a
solvent in which all foldamers were well soluble, and
diluted to a concentration appropriate for UV absorbance
measurement. This was subsequently carried out at
375 nm, corresponding to a local maximum of the quino-
line oligoamide foldamer absorbance. The extinction coef-
ﬁcient at this wavelength had previously been calculated
by measuring the absorbance of serial dilutions of an NMR
sample of 8, for which the concentration had been assessed
by comparison with an internal calibrant (see Supporting
information). From this, the original concentration of fol-
damer in each solvent could be extrapolated, serving as an
accurate measure of solubility. As shown in Table 1, there
are signiﬁcant differences in the solubility proﬁle imparted
by the adjustment of side-chain length. As we had antici-
pated, the tetraethylene glycol side-chain permitted a
reasonable (mM) solubility of 8 in pure water. In contrast,
the other octamers showed negligible aqueous solubility.tionalized octamers.
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the other solvents apart from n-hexane and isopropanol,
similarly to the remaining compounds.
The behavior of the triethylene glycol-functionalized
octamer 7 matched well with our previous experiment,
which demonstrated similar properties to 8, with the
difference that solubility in protic solvents was dimin-
ished by at least one order of magnitude. Decreasing the
side-chain length further to diethylene glycol (6)
decreased the solubility of the octamer to sub-millimolar
levels in both toluene and methanol, with limited effects
on other solvents. Finally, as anticipated, the mono-
ethylene glycol-functionalized octamer 5 showed a
marked reduction in solubility in all polar solvents,
although this was also accompanied by a near doubling of
solubility in chloroform compared to 7, the next most
soluble oligomer in this solvent. These results show that
the solubility properties of the quinoline-based foldamers
can be effectively tailored by altering the length of OEG-
based side-chains, allowing access to highly soluble
oligomers compatible with both water and a range of
organic solvents.
2.3. Chiral HPLC
During studies of the tetraethylene glycol-
functionalized octamer 8, it became clear to us that its
highly soluble nature could be taken as an advantage, with
respect to the separation of helix handedness forms. We
have previously demonstrated that the handedness
inversion kinetics of the quinoline oligoamide foldamers
are highly solvent dependent, with an octameric sequence
similar to that of 7 demonstrating half lives varying from
minutes in aprotic solvents to days in protic solvents
[11(b)]. In water, kinetics are essentially frozen: aqueous
solutions of separated P and M helices of octamers have
been left at room temperature for months and demon-
strated no evidence of handedness inversion [15]. Sepa-
ration of P and M helices of water-soluble oligomers was
previously carried out using a phenylalanine unit installed
at the C-terminus to permit RP-HPLC separation of the two
helix forms as diastereoisomers. In contrast, we envisaged
that the good solubility of 8 in both organic and aqueous
solvents would permit the use of chiral HPLC to separate
the two helix handedness forms as enantiomers. If left in
the solid state, or if dissolved in water handedness would
remain ‘locked’. This strategy proved to be valid as weTable 1
Estimated solubility (mM) of foldamers 5e8 in each solvent.
Solvent Estimated solubility (mM)
5 6 7 8
Hexane <0.01 <0.01 <0.01 <0.01
Toluene 0.20 0.28 55 69
Chloroform 158 39 86 59
THF 13 70 64 85
DMF 21 73 105 88
Isopropanol 0.02 0.03 0.03 0.27
Methanol 0.04 0.13 1.5 20
Water <0.01 <0.01 <0.01 2.5successfully used a standard Chiralpak-IA chiral analytical
HPLC column to separate the P and M helix forms of
compound 8 at low temperature (Fig. 3a, b) in organic
solvents. In-line circular dichroism demonstrated elution
of the M-helix as the ﬁrst peak, followed by the P-helix;
these could be isolated with ee values of >99% and 93%
respectively (Fig. 3c, d). Conveniently, handedness inver-
sion kinetics in the solvent mixture and temperature used
for chiral HPLC (MeOH/CHCl3, 75:25, 5 C) appeared to
be extremely slow: the isolated M helix was subsequently
incubated for up to eight hours under these conditions,
with no visible racemization (see Supporting information).
We could also use the same column to separate one-
handed forms of the monoethylene glycol-functionalized
octamer 5 at room temperature, and this also demon-
strated the same order of elution as compound 8 (see
Supporting information).
In summary, the tetraethylene glycol side-chains allow
facile separation of P and M helices by using chiral HPLC in
organic solvents, yet also permit solubility under aqueous
conditions where helix handedness inversion kinetics are
essentially frozen. For oligomers bearing these side-chains,
this could conceivably be a convenient method to isolate
usable quantities of separate handedness forms without
requiring the installation of chiral groups for handedness
induction, or separation of diastereoisomers.
3. Conclusions
Four Fmoc-acid quinoline monomers have been syn-
thesized with OEG side-chains installed at position four
through an acid-stable thioether linkage. The general
methodology for their preparation is compatible with the
production of monomers possessing longer OEG units;
indeed probably the main limiting factor is the commer-
cial availability of the OEG monomethyl ether starting
material. From these monomers four octameric sequences,
each consisting exclusively of one monomer type, were
synthesized by a microwave-assisted SPS methodology.
Their solubility proﬁles were investigated and it was
shown that elongation of the side-chain unit to tetra-
ethylene glycol permitted excellent solubility of the cor-
responding octameric sequence (8) in the majority of
organic solvents studied. More importantly, this com-
pound was also found to possess modest solubility in pure
water, which has not been demonstrated before in quin-
oline oligoamide foldamers without the presence of mul-
tiple charged side-chains. The P and M helix handedness
forms of octamer 8 were separated using a standard chiral
HPLC stationary phase, providing for the ﬁrst time a
method to isolate water-soluble helices as their separate
enantiomers, without requiring chiral groups for
handedness induction, or separation of the respective
diastereoisomers.
Future work will investigate the use of OEG function-
alized monomer units in sequences designed to interact
with biomolecules. While providing foldamers with the
necessary aqueous solubility, we foresee that monomers
such as 8 can also have a potential role in eliminating un-
desired non-speciﬁc interactions of the foldamer backbone
with a biological target.
Fig. 3. Chiral HPLC separation of P and M helices of compound 8 at 5 C in
MeOH/CHCl3 (75:25). Expansion of: (a) UV detector trace (254 nm); (b) CD
detector trace (385 nm). Overlaid expansions of isolated P-8 (gray) and M-8
(black); (c) UV detector traces (254 nm); (d) CD detector traces (385 nm).
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4.1. General methods
Sieber amide resin was purchased from Novabiochem.
Ghosez reagent (1-chloro-N,N,2-trimethyl-1-
propenylamine) was purchased from SigmaeAldrich. N,N-
diisopropylethylamine was distilled over calcium hydride.
Analytical grade organic solvents were used for solid phase
synthesis. Anhydrous THF and CH2Cl2 for solution and solid
phase synthesis were dispensed from an MBRAUN SPS-800
solvent puriﬁcation system. HPLC grade acetonitrile andMilliQ water were used for RP-HPLC analyses and puriﬁ-
cation. Reactions requiring anhydrous conditions were
performed under nitrogen. SPS was carried out manually
using a CEM Discover microwave and vacuum station, and
in proprietary reactor vessels. 1H NMR spectra were
measured at 300MHz and 13C NMR spectra were measured
at 75 MHz. Chemical shifts are reported in ppm and are
calibrated against residual solvent signals of CDCl3 (d 7.26,
77.2), or DMSO-d6 (d 2.50, 39.4). All coupling constants are
reported in hertz (Hz). Signals were abbreviated as s,
singlet; br s, broad singlet; d, doublet; t, triplet; q, quartet;
m, multiplet, dd, doublet of doublets. Silica gel chroma-
tographywas performed using aMerck Kieselgel Si 60. Thin
layer chromatography was performed using Merck Kie-
selgel Si 60 F254 plates. Recycling gel permeation chro-
matography was performed at 37 C on a JAI LC-9130G
NEXT using a JAIGEL 2.5H or a JAIGEL 3H column
(20  600 mm) with chloroform (HPLC grade, ethanol
stabilized) as the eluent running at 3.5 mL min1. Chiral
analytical HPLC was performed using a Daicel Chiralpak IA
column with either isocratic ethyl acetate/chloroform
(50:50) or methanol/chloroform (75:25) as the eluent
running at 0.5 mL min-1 at room temperature (compound
5) or 1.0 mL min1 at 5 C (compound 8). RP-HPLC ana-
lyses were performed at 1.5 mL min1 using a Macherey-
Nagel Nucleodur C18 or C8 Gravity column (4.6  100 mm,
3 mm). The mobile phase was composed of 0.1% (v/v) TFA-
H2O (Solvent A) and 0.1% TFA-CH3CN (Solvent B) running
the following gradients: 50e100% B over 15 min (System
A), 40e90% B over 20 min (System B), or 50e100% B over
20 min (System C). Monitoring by UV detectionwas carried
out at 214 nm, 254 nm and 300 nm using a diode array
detector. Semi-preparative puriﬁcations of oligomers were
performed at 4 mL min1 on a semipreparative HPLC using
a Macherey-Nagel Nucleodur C18 HTEC column
(21 mm  125 mm, 5 mm). The mobile phase was the same
as that for the analytical system, running the following
gradients: 50e100% B over 20 min (System D), 40e90% B
over 15 min (System E), or 10e100% B over 25 min (System
F). Monitoring by UV detection was carried out at 254 nm
and 300 nm using a diode array detector. High resolution
electrospray ionization time of ﬂight (ESI-TOF) mass
spectra were measured in the positive ion mode on a Wa-
ters/Micromass Q-Tof Ultima. X-ray diffraction experiments
were carried out on a high ﬂux RIGAKU FRX rotating anode
at the Cu Ka wavelength.
CCDC-1056802 for monomer 4 contains the supple-
mentary crystallographic data for this paper. These data can
be obtained free of charge from The Cambridge Crystallo-
graphic Data Centre via www.ccdc.cam.ac.uk/data_request/
cif.
4.2. Monomer synthesis
2-Methoxyethanethiol was commercially available
while the other 3 thiols [2-(2-methoxyethoxy)ethanethiol,
2-(2-(2-methoxyethoxy)ethoxy)ethanethiol, 2,5,8,11-
tetraoxatridecane-13-thiol] were synthesized according to
literature procedures [22]. Methyl 4-bromo-8-
nitroquinoline-2-carboxylate was prepared as previously
reported [14(b)]. Fmoc-monomers 1e4 were produced
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below by the synthesis of compound 1 and its corre-
sponding intermediates:
4.2.1. General procedure for nucleophilic aromatic substitution
4.2.1.1. Methyl 4-(2-methoxyethylthio)-8-nitroquinoline-2-car-
boxylate. Methyl 4-bromo-8-nitroquinoline-2-carboxylate
(2.5 g, 8.0 mmol) and Cs2CO3 (3.9 g, 12.0 mmol, 1.5 equiv)
were suspended in 75 mL anhydrous DMF. 2-
Methoxyethanethiol (815 mg, 8.8 mmol, 1.1 equiv) was
added and the resulting slurry stirred at room temperature
for 48 h under N2. The reaction mixture was then diluted
with brine, extracted with EtOAc and the combined organic
phases were dried over Na2SO4, ﬁltered, and evaporated.
Recrystallization in DCM/MeOH afforded the title com-
pound as an orange solid (1.8 g, 71%). 1H NMR (CDCl3):
d 8.39 (1H, dd, J ¼ 8.6, 1.3), 8.12 (1H, s), 8.08 (1H, dd, J ¼ 7.5,
1.2), 7.69 (1H, dd, J ¼ 8.6, 7.4), 4.04 (3H, s), 3.81 (2H, t,
J ¼ 6.0), 3.44 (2H, t, J ¼ 5.9), 3.44 (3H, s). 13C NMR (CDCl3):
d 128.17, 127.67, 126.92, 124.79, 117.02, 69.91, 59.26, 53.59,
31.76. HRMS (ESþ): m/z calcd for C14H15N2O5S [MþH]þ
323.0696 found 323.0702.
4.2.1.2. Methyl 4-(2-(2-methoxyethoxy)ethylthio)-8-nitroquin
oline-2-carboxylate. Synthesized using the general meth-
odology mentioned above. Puriﬁcation by silica gel chro-
matography (cyclohexane/EtOAc (6:4) to cyclohexane/
EtOAc (4:6)) followed by precipitation in DCM/MeOH
afforded the title compound as a yellow solid (2.3 g, 78%).
1H NMR (CDCl3): d 8.38 (1H, dd, J ¼ 8.5, 1.3), 8.12 (1H, s),
8.07 (1H, dd, J¼ 7.4, 1.3), 7.69 (1H, dd, J ¼ 8.5, 7.5), 4.03 (3H,
s), 3.90 (2H, t, J ¼ 6.2), 3.71e3.66 (2H, m), 3.58e3.54 (2H,
m), 3.46 (2H, t, J ¼ 6.3), and 3.38 (3H, s). 13C NMR (CDCl3):
d 165.60, 150.74, 149.34, 148.91, 138.73, 128.19, 127.69,
126.88, 124.77, 117.10, 72.06, 70.85, 68.85, 59.30, 53.56,
31.69. HRMS (ESþ): m/z calcd for C16H19N2O6S [MþH]þ
367.0958 found 367.0968.
4.2.1.3. Methyl 4-(2-(2-(2-methoxyethoxy)ethoxy)ethylthio)-8-
nitroquinoline-2-carboxylate. Synthesized using the general
methodology mentioned above. Puriﬁcation by silica gel
chromatography (cyclohexane/EtOAc (8:2) to cyclohexane/
EtOAc (1:1)) afforded the title compound as a yellow solid
(2.3 g, 71%). 1H NMR (CDCl3): d 8.36 (1H, dd, J¼ 8.6,1.3), 8.11
(1H, s), 8.06 (1H, dd, J ¼ 7.5, 1.3), 7.68 (1H, dd, J ¼ 8.4, 7.5),
4.02 (3H, s), 3.89 (2H, t, J ¼ 6.2), 3.72e3.60 (6H, m),
3.54e3.49 (2H, m), 3.44 (2H, t, J¼ 6.2), 3.35 (3H, s). 13C NMR
(CDCl3): d 165.64, 150.86, 149.38, 148.94, 138.75, 128.21,
127.71, 126.95, 124.81, 117.14, 72.15, 70.98, 70.85, 68.89,
59.27, 53.60, 31.82. HRMS (ESþ): m/z calcd for C18H23N2O7S
[MþH]þ 411.1226 found 411.1226.
4.2.1.4. Methyl 4-(2,5,8,11-tetraoxatridecan-13-ylthio)-8-nitro-
quinoline-2-carboxylate. Synthesized using the general
methodology mentioned above. Puriﬁcation by silica gel
chromatography (cyclohexane/EtOAc (8:2) to cyclohexane/
EtOAc (1:1)) followed by crystallization from Et2O at 4 C
afforded the title compound as awhite solid (2.0 g, 54%). 1H
NMR (CDCl3): d 8.39 (1H, dd, J ¼ 8.6, 1.3), 8.13 (1H, s), 8.07(1H, dd, J ¼ 7.5, 1.3), 7.69 (1H, dd, J ¼ 8.5, 7.5), 4.04 (3H, s),
3.90 (2H, t, J ¼ 6.2), 3.73e3.61 (10H, m), 3.56e3.51 (2H, m),
3.45 (2H, t, J ¼ 6.2), 3.37 (3H, s). 13C NMR (CDCl3): d 165.73,
150.91,149.46,149.02,128.30,127.79,126.99,124.86, 117.20,
72.22, 71.04, 70.94, 70.90, 70.88,70.82, 68.92, 59.32, 53.67,
and 31.88. HRMS (ESþ): m/z calcd for C10H26N2O8S [MþH]þ
455.1483 found 455.1493
4.2.2. General procedure for saponiﬁcation of methyl ester
4.2.2.1. 4-(2-Methoxyethylthio)-8-nitroquinoline-2-carboxylic
acid. 4-(2-methoxyethylthio)-8-nitroquinoline-2-carboxy-
late (1.8 g, 5.6 mmol) was dissolved in 280 mL THF/H2O
(4:1). LiOH$H2O (470 mg, 11.2 mmol, 2 equiv) was added
and the reaction was stirred for 45 min at room tempera-
ture. 5% w/v citric acid solutionwas then added to reach pH
4, THF was evaporated under reduced pressure and the
resulting aqueous mixture was extracted with DCM. The
combined organic phases werewashedwith H2O and brine,
dried over Na2SO4, ﬁltered and evaporated to yield the title
compound as a yellow solid (1.7 g, 97%). 1H NMR (CDCl3):
d 8.47 (1H, dd, J¼ 8.6,1.2), 8.21 (1H, dd, J¼ 7.6,1.1), 8.21 (1H,
s), 7.77 (1H, dd, J ¼ 8.3, 7.6), 3.83 (2H, t, J ¼ 5.9), 3.49 (2H, t,
J ¼ 5.9), 3.44 (3H, s). 13C NMR (CDCl3): d 163.53, 153.81,
148.03,146.48,136.91,128.43,128.25,127.44,126.00,114.76,
69.70, 59.27, 31.95. HRMS (ESþ): m/z calcd for C13H13N2O5S
[MþH]þ 309.0540 found 309.0551.
4.2.2.2. 4-(2-(2-Methoxyethoxy)ethylthio)-8-nitroquinoline-2-
carboxylic acid. Synthesized using the general methodology
mentioned above to afford the title compound as a yellow
solid (1.8 g, 96%). 1H NMR (CDCl3): d 8.44 (1H, dd, J ¼ 8.6,
1.2), 8.20 (1H, s), 8.19 (1H, dd, J ¼ 7.0, 1.3), 7.75 (1H, dd,
J ¼ 8.6, 7.6), 3.92 (2H, t, J ¼ 5.9), 3.71e3.66 (2H, m),
3.59e3.54 (2H, m), 3.49 (2H, t, J¼ 6.1), 3.37 (3H, s). 13C NMR
(CDCl3): d 163.51, 153.83, 148.02, 146.50, 136.90, 128.45,
128.28, 127.39, 125.96, 114.92, 72.03, 70.85, 68.71, 59.26.
HRMS (ESþ): m/z calcd for C15H17N2O6S [MþH]þ 353.0802
found 353.0812.
4.2.2.3. 4-(2-(2-(2-Methoxyethoxy)ethoxy)ethylthio)-8-nitroquino-
line-2-carboxylic acid. Synthesized using the general meth-
odology mentioned above to afford the title compound as a
yellow solid (1.9 g, 98%). 1H NMR (CDCl3): d 8.46 (1H, dd,
J ¼ 8.6, 1.2), 8.24 (1H, s), 8.20 (1H, dd, J ¼ 7.6, 1.2), 7.76 (1H, dd,
J ¼ 8.5, 7.7), 3.93 (2H, t, J ¼ 6.0), 3.74e3.62 (6H, m), 3.55e3.51
(2H, m), 3.49 (2H, t, J ¼ 6.0), 3.36 (3H, s). 13C NMR (CDCl3):
d 163.50, 153.95, 148.10, 146.53, 136.96, 128.53, 128.31, 127.40,
125.98, 114.98, 72.11, 71.00, 70.81, 68.80, 59.22, 32.02. HRMS
(ESþ): m/z calcd for C17H21N2O7S [MþH]þ 397.1069 found
397.1073.
4.2.2.4. 4-(2,5,8,11-Tetraoxatridecan-13-ylthio)-8-nitroquino-
line-2-carboxylic acid. Synthesized using the general
methodology mentioned above to afford the title com-
pound as a yellow solid (1.6 g, 93%). 1H NMR (CDCl3):
d 8.43 (1H, d, J ¼ 8.5), 8.20 (1H, s), 8.19 (1H, d, J ¼ 7.3), 7.76
(1H, t, J ¼ 8.0), 3.94 (2H, t, J ¼ 6.0), 3.75e3.60 (10H, m),
3.58e3.52 (2H, m), 3.49 (2H, t, J ¼ 6.0), 3.37 (3H, s). 13C
NMR (CDCl3): d 163.72, 153.53, 147.99, 146.76, 136.93,
C. Tsiamantas et al. / C. R. Chimie 19 (2016) 132e142 139128.28, 128.15, 127.26, 125.80, 115.05, 71.99, 70.85, 70.71,
70.66, 70.55, 68.64, 59.09, 53.58, 31.89. HRMS (ESþ): m/z
calcd for C19H25N2O8S [MþH]þ 441.1326 found 441.1331.
4.2.3. General procedure for reduction of nitro group
4.2.3.1. 8-Amino-4-(2-methoxyethylthio)quinoline-2-carboxylic
acid. 4-(2-methoxyethylthio)-8-nitroquinoline-2-carboxy-
lic acid (1.6 g, 5.2 mmol) was dissolved in 375 mL EtOAc/
EtOH (4:1), 10% Pd/C (0.16 g, 10% by mass) and NH4VO3
(124 mg, 1.1 mmol, 0.2 equiv) were added and the mixture
was heated to reﬂux (bath temperature 95 C). A solution of
NH4HCO2 (15.7 g, 248 mmol, 48 equiv) in 12 mL H2O was
then added drop-wise to the reaction mixture over 10 min
and the mixture stirred for 4 h under reﬂux. The reaction
mixture was cooled to room temperature, EtOAc added and
the resulting solution ﬁltered on Celite. The organic phase
was washed with water and brine, dried over Na2SO4,
ﬁltered, and solvents were evaporated under reduced
pressure to yield the title compound as an orange-red oil,
which was used directly in the next step without further
puriﬁcation. 1H NMR (DMSO-d6): d 12.83 (1H, s), 7.90 (1H, s),
7.42 (1H, t, J ¼ 8.0), 7.12 (1H, dd, J ¼ 8.2, 1.0), 6.89 (1H, dd,
J ¼ 7.8, 1.0), 6.63 (2H, br s), 3.70 (2H, t, J ¼ 6.0), 3.43 (2H, t,
J ¼ 6.0), 3.31 (3H, s).
4.2.3.2. 8-Amino-4-(2-(2-methoxyethoxy)ethylthio)quinoline-2-
carboxylic acid. 1H NMR (DMSO-d6): d 12.83 (1H, s), 7.92 (1H,
s), 7.42 (1H, t, J ¼ 8.0), 7.12 (1H, dd, J ¼ 8.3, 1.1), 6.89 (1H, dd,
J¼ 7.7,1.1), 6.63 (2H, br s), 3.77 (2H, t, J¼ 6.1), 3.61e3.56 (2H,
m), 3.48e3.39 (4H, m), 3.23 (3H, s).
4.2.3.3. 8-Amino-4-(2-(2-(2-methoxyethoxy)ethoxy)ethylthio)
quinoline-2-carboxylic acid. 1H NMR (DMSO-d6): d 7.91 (1H,
s), 7.37 (1H, t, J¼ 7.9), 7.11 (1H, d, J¼ 8.0), 6.87 (1H, d,
J¼ 7.5), 6.45 (2H, br s), 3.77 (2H, t, J¼ 6.1), 3.62e3.46 (6H,
m), 3.44e3.35 (4H, m), 3.21 (3H, s).
4.2.3.4. 4-(2,5,8,11-Tetraoxatridecan-13-ylthio)-8-aminoquino-
line-2-carboxylic acid. 1H NMR (CD3OD): d 8.13 (1H, s),
7.43e7.30 (2H, m), 6.98 (1H, dd, J ¼ 7.1, 1.3), 3.88 (2H, t,
J ¼ 6.4), 3.72e3.56 (10H, m), 3.54e3.48 (2H, m), 3.43 (2H, t,
J ¼ 6.4).
4.2.4. General procedure for Fmoc installation
4.2.4.1. 8-((((9H-ﬂuoren-9-yl)methoxy)carbonyl)amino)-4-((2-
methoxyethyl)thio)quinoline-2-carboxylic acid (1). 8-Amino-
4-(2-methoxyethylthio)quinoline-2-carboxylic acid (1.2 g,
4.1 mmol) was dissolved in 22 mL 1,4-dioxane, 73 mL of a
10% w/v aqueous solution of NaHCO3 was added, and the
mixture was stirred at 0 C (ice-bath) under N2. 1.2 g of
Fmoc-Cl (1.2 g, 4.5 mmol, 1.1 equiv) was dissolved in 63 mL
1.4-dioxane, and added dropwise via a dropping funnel
under N2 over approximately 1 h. The mixture was then
stirred at 0 C for a further 1 h and then at rt for 20 h.
Approximately 100 mL H2O was then added, and the
resulting mixture acidiﬁed to pH 6 by portion-wise addi-
tion of 1 M HCl. The mixture was then extracted with DCM
and the combined organic phases washed with brine, driedover Na2SO4 ﬁltered and evaporated under reduced pres-
sure. Puriﬁcation by silica gel chromatography (100% DCM
to DCM/MeOH 9:1), followed by crystallization in DCM
afforded the title compound as a white solid (1.1 g, 43%). 1H
NMR (DMSO-d6): d 13.59 (1H, s), 10.44 (1H, s), 8.06 (1H, s),
7.93 (2H, d, J ¼ 7.4), 7.80e7.72 (3H, m), 7.67 (1H, t, J ¼ 8.3),
7.47e7.33 (4H, m), 4.62 (2H, d, J ¼ 6.7), 4.45 (1H, t, J ¼ 6.8),
3.72 (2H, t, J¼ 6.0), 3.51 (2H, t, J¼ 6.0), 3.31 (3H, s). 13C NMR
(DMSO-d6): d 165.40, 153.52, 149.98, 144.30, 143.78, 140.89,
136.42, 135.62, 129.33, 127.85, 127.28, 126.65, 125.23,
120.29, 116.50, 116.05, 114.75, 69.41, 66.54, 58.13, 46.68,
30.38. HRMS (ESþ): m/z calcd for C28H25N2O5S [MþH]þ
501.1479 found 501.1478.
4.2.4.2. 8-((((9H-ﬂuoren-9-yl)methoxy)carbonyl)amino)-4-(2-
(2-methoxyethoxy)ethylthio)quinoline-2-carboxylic acid (2).
Synthesized using the general methodology mentioned
above to afford the title compound as a white solid (0.96 g,
68%). 1H NMR (DMSO-d6): d 7.99 (1H, s), 7.92 (2H, d, J¼ 7.2),
7.74 (2H, d, J ¼ 7.3), 7.66 (1H, d, J ¼ 8.1), 7.53 (1H, t, J ¼ 7.8),
7.47e7.32 (4H, m), 4.64 (2H, d, J ¼ 6.1), 4.43 (1H, t, J ¼ 6.2),
3.76 (2H, t, J ¼ 6.2), 3.60e3.55 (2H, m), 3.47e3.42 (2H, m),
3.40 (2H, t, J ¼ 6.1), 3.23 (3H, s). 13C NMR (DMSO-d6):
d 167.67, 152.85, 150.73, 147.84, 143.59, 140.70, 135.79,
135.34, 128.87, 127.63, 127.12, 125.70, 124.96, 121.32, 119.97,
116.27, 115.89, 115.05, 69.24, 66.33, 57.85, 54.89, 46.49,
30.22. HRMS (ESþ): m/z calcd for C30H29N2O6S [MþH]þ
545.1741 found 545.1750.
4.2.4.3. 8-((((9H-ﬂuoren-9-yl)methoxy)carbonyl)amino)-4-(2-
(2-(2-methoxyethoxy)ethoxy)ethylthio)quinoline-2-carboxylic
acid (3). Synthesized using the general methodology
mentioned above. Puriﬁcation by silica gel chromatography
(100% DCM to DCM/MeOH 92:8) followed by precipitation
in DCM afforded the title compound as a white solid (1.2 g,
67%). 1H NMR (DMSO-d6): d 13.60 (1H, s), 10.47 (1H, s), 8.38
(1H, br s), 8.08 (1H, s), 7.93 (2H, d, J ¼ 7.2), 7.81e7.72 (3H,
m), 7.67 (1H, t, J ¼ 8.1), 7.47e7.31 (4H, m), 4.62 (2H, d,
J ¼ 6.8), 4.45 (1H, t, J ¼ 6.6), 3.80 (2H, t, J ¼ 6.1), 3.62e3.45
(8H, m), 3.40e3.35 (2H, m), 3.31 (2H, br s), 3.20 (2H, s). 13C
NMR (DMSO-d6): d 165.35, 153.41, 149.86, 144.36, 143.67,
140.79, 136.31, 135.56, 129.20, 127.74, 127.18, 126.58, 125.12,
120.19, 116.35, 115.97, 114.83, 71.22, 69.81, 69.74, 69.59,
68.05, 66.44, 64.89, 57.99, 46.57, 30.47, 15.13. HRMS (ESþ):
m/z calcd for C32H33N2O7S [MþH]þ 589.2003 found
589.2017.
4.2.4.4. 8-((((9H-ﬂuoren-9-yl)methoxy)carbonyl)amino)-4-
(2,5,8,11-tetraoxatridecan-13-ylthio)-8-aminoquinoline-2-
carboxylic acid (4). Synthesized using the general
methodology mentioned above. Puriﬁcation by silica gel
chromatography (100% DCM to DCM/MeOH 9:1) affor-
ded the title compound as a white solid (1.1 g, 73%). 1H
NMR (DMSO-d6): d 10.01 (1H, s), 8.31 (1H, s), 8.25 (1H, s),
8.05 (1H, s), 7.89 (2H, d, J ¼ 7.4), 7.74e7.64 (3H, m), 7.58
(1H, t, J ¼ 7.8), 7.40 (2H, t, J¼ 7.3), 7.31 (2H, t, J¼ 7.2), 4.55
(2H, d, J ¼ 6.4), 4.36 (1H, t, J ¼ 6.6), 3.74 (2H, t, J ¼ 5.8),
3.58e3.54 (14H, m), 3.20 (3H, s). 13C NMR (DMSO-d6):
d 153.06, 148.55, 143.61, 140.72, 135.73, 128.87, 128.25,
127.68, 127.15, 126.06, 125.02, 121.33, 120.16, 119.97,
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69.51, 67.98, 66.38, 57.98, 46.48, 30.40. HRMS (ESþ): m/z
calcd for C34H37N2O8S [MþH]þ 633.2265 found
633.2259.
4.3. General procedure for SPS of octamers
Octamers 5e8 were produced using the same general
methodology, exempliﬁed here by the synthesis of com-
pound 5:
4.3.1. Monomer activation
4.3.1.1. Compound 1-Cl. Compound 1 (49 mg, 0.098 mmol,
6 equiv relative to resin loading) was suspended in anhy-
drous CH2Cl2 (2 mL) under N2. Ghosez reagent was added
(26 mL, 0.195mmol, 2 equiv) and the reactionwas stirred for
1 h at rt under N2. Solvents were evaporated under reduced
pressure on a vacuum line (approximately 2 h).
4.3.1.2. 4-(2-Methoxyethylthio)-8-nitroquinoline-2-carbonyl
chloride. 4-(2-Methoxyethylthio)-8-nitroquinoline-2-carbo-
xylic acid (30.2mg, 0.098mmol, 6 equiv)was activated in the
same manner as described above.
4.3.2. SPS
4.3.2.1. Compound 5. Synthesized on a 16.3 mmol scale
(25 mg Sieber amide resin with manufacturer's loading:
0.65 mmol g1). The resin was initially swollen for 1 h in
DMF. Fmoc deprotection: the resin was stirred in a 20% v/v
solution of piperidine in DMF at rt for 10 min, reagents
were removed under vacuum, the resin was washed with
DMF brieﬂy, and treatment was repeated twice. The resin
was then washed thoroughly with DMF. Coupling of
monomer acid chlorides (also the loading method for com-
pounds 5e7): The resin was washed thoroughly with
anhydrous THF, then suspended in 1.3 mL anhydrous THF,
to which anhydrous DIEA (34 mL, 0.196 mmol, 6 equiv) was
added. Compound 1-Cl (assuming complete conversion to
acid chloride, 0.098 mmol, 6 equiv) was dissolved in
2.6 mL anhydrous THF under N2, and 1.3 mL of this solu-
tion (i.e. 3 equiv of acid chloride) was added to the resin
which was then treated with microwaves (50 W, 50 C,
5 min). The resin was washed brieﬂy with anhydrous THF
and the process was repeated with the remaining acid
chloride solution. The resin was then thoroughly washed
with anhydrous THF, then DMF. Coupling of the N-termi-
nal nitro-functionalized quinoline monomer 4-(2-
methoxyethylthio)-8-nitroquinoline-2-carbonyl chloride
was carried out in the same manner. Resin cleavage: the
resin was washed thoroughly with DMF, DCM and DCM/
MeOH (1:1), dried and desiccated. It was then suspended
in 2 mL of TFA/DCM (1:1 v/v) and stirred at rt for 1 h. The
resin was removed by ﬁltration and solvents were evap-
orated under reduced pressure to yield the crude product.
This was puriﬁed by recycling GPC (due to the limited
solubility under RP-HPLC conditions) and followed by an
additional crystallization in DCM/MeOH to afford the title
compound as a yellow solid (8 mg, 20%). 1H NMR (CDCl3):d 11.43 (1H, s), 11.13 (1H, s), 11.03 (1H, s), 10.99 (3H, s),
10.91 (1H, s), 8.23 (1H, dd, J ¼ 7.0, 2.6), 8.17e8.11 (3H, m),
8.03 (1H, dd, J ¼ 7.8, 1.1), 8.00 (1H, dd, J ¼ 8.4, 1.2), 7.95
(1H, dd, J ¼ 8.5, 1.1), 7.82e7.74 (3H, m), 7.67e7.57 (3H, m),
7.56e7.47 (3H, m), 7.47e7.28 (9H, m), 7.22 (1H, d, J ¼ 7.8),
7.11 (1H, d, J ¼ 8.1), 7.07 (1H, s), 7.01 (1H, s), 6.96 (1H, s),
6.91 (1H, s), 6.88 (1H, s), 6.57 (1H, s), 6.40 (1H, d, J ¼ 4.0),
4.18 (1H, d, J ¼ 4.0), 4.08e3.96 (4H, m), 3.93e3.73 (10H,
m), 3.68 (3H, s), 3.66 (3H, s), 3.61 (3H, s), 3.56 (3H,s), 3.55
(3H, s), 3.52 (3H, s), 3.49 (3H, s), and 3.47e3.07 (21H, m).
13C NMR (CDCl3): d 164.74, 163.72, 163.12, 160.61, 160.51,
160.03, 159.96, 159.33, 58.89, 158.82, 154.92, 152.28,
151.34, 150.86, 150.78, 150.63, 150.52, 150.14, 149.89,
149.73, 149.63, 149.36, 147.17, 146.31, 146.20, 146.12, 145.97,
145.56, 145.47, 144.67, 144.51, 137.37, 136.28, 136.10, 136.02,
135.97, 135.64, 135.48, 134.73, 134.20, 133.53, 133.41,
133.32, 133.00, 132.89, 129.15, 128.44, 128.34, 128.22,
127.66, 127.63, 127.56, 127.45, 127.41, 127.35, 127.23, 127.12,
127.02, 126.98, 126.91, 126.86, 126.68, 125.88, 125.82,
125.15, 125.12, 118.86, 118.70, 118.40, 118.22, 117.94, 117.24,
117.09, 116.73, 116.03, 115.63, 114.47, 113.99, 113.23, 112.83,
112.41, 112.25, 112.13, 111.95, 70.71, 70.44, 70.11, 59.47,
59.45, 59.42, 59.40, 59.34, 59.31, 59.24, 31.70, 31.48, 31.38,
31.27, 31.23. HRMS (ESþ): m/z calcd for C104H98N17O18S8
[MþH]þ 2128.5042 found 2128.5109.
4.3.2.2. Compound 6. Synthesized on a 32.5 mmol scale
(50 mg Sieber amide resin with manufacturer's loading:
0.65 mmol g1) using the general methodology mentioned
above. The crude product was puriﬁed by preparative RP-
HPLC (System D) to afford the title compound as a yellow
solid (22 mg, 28%). RP-HPLC (System A): Rt ¼ 18.17 min 1H
NMR (CDCl3): d 11.42 (1H, s),11.13 (1H, s),11.03 (1H, s),11.00
(1H, s), 10.99 (1H, s), 10.97 (1H, s), 10.90 (1H, s), 8.27e8.20
(1H, m), 8.19e8.11 (3H, m), 8.06e8.92 (3H, m), 7.82e7.74
(3H, m), 7.68e7.56 (3H, m), 7.55e7.47 (3H, m), 7.46e7.28
(8H, m), 7.20 (1H, d, J ¼ 7.2), 7.15e7.05 (3H, m), 7.04 (1H, s),
6.96 (1H, s), 6.93 (1H, s), 6.88 (1H, s), 6.56 (1H, s) 6.38 (1H,
br s), 4.59 (1H, br s) 4.20e3.97 (14H, m), 3.90e3.60 (m,
50H), 3.57 (3H, s), 3.56 (3H, s), 3.55 (3H, s), 3.49 (3H, s), 3.46
(3H, s), 3.44 (3H, s), 3.43 (3H, s), 3.40 (3H, s). HRMS (ESþ):
m/z calcd for C120H130N17O26S8 [MþH]þ 2480.7139 found
2480.7204.
4.3.2.3. Compound 7. Synthesized on a 32.5 mmol scale
(50 mg Sieber amide resin with manufacturer's loading:
0.65 mmol g1) using the general methodology
mentioned above. The crude product was puriﬁed by
preparative RP-HPLC (System E) to afford the title com-
pound as a yellow solid (14 mg, 15%). RP-HPLC (System B):
Rt ¼ 8.98 min 1H NMR (CDCl3): d 11.42 (1H, s), 11.12 (1H,
s), 11.03 (1H, s), 10.98 (3H, s), 10.89 (1H, s), 8.26e8.19 (1H,
m), 8.18e8.10 (3H, m), 8.07e7.92 (3H, m), 7.82e7.73 (3H,
m), 7.69e7.56 (3H, m), 7.55e7.47 (3H, m), 7.47e7.29 (8H,
m), 7.22e7.18 (1H, m), 7.12 (1H, s), 7.10e7.05 (1H, m), 7.04
(1H, s), 6.96 (1H, s), 6.93 (1H, s), 6.88 (1H, s), 6.56 (1H, s),
6.35 (1H, s), 4.67 (1H, s), 4.19e4.05 (4H, m), 4.00e3.52
(92H, m), 3.48 (6H, s), 3.45 (3H, s), 3.42 (3H, s), 3.41 (3H,
s), 3.39 (3H, s), 3.37 (3H, s), 3.31 (3H, s). HRMS (ESþ): m/z
C. Tsiamantas et al. / C. R. Chimie 19 (2016) 132e142 141calcd for C136H162N17O34S8 [MþH]þ 2832.9236 found
2832.9309.
4.3.2.4. Compound 8. Synthesized on a 16.3 mmol scale
(25 mg Sieber amide resin with manufacturer's loading:
0.65 mmol g1) using the general methodology mentioned
above, with the exception that loading of the ﬁrst monomer
was carried out using HBTU (18.5 mg, 0.049mmol, 3 equiv),
and HOBt (7.5 mg, 0.049 mmol, 3 equiv) in the presence of
DIEA (17 mL, 0.098 mmol, 6 equiv) with 1 mL DMF as the
solvent and treated with microwaves (25 W, 70 C, 10 min).
Loading was repeated once. The crude product was puriﬁed
by preparative RP-HPLC (System F) and then by recycling
GPC to afford the title compound as a yellow solid (7 mg,
14%). RP-HPLC (System C): Rt ¼ 11.33 min 1H NMR (CDCl3):
d 11.45 (1H, s), 11.14 (1H, s), 11.06 (1H, s), 11.01 (2H, s), 11.00
(1H, s), 10.91 (1H, s), 8.27 (1H, m), 8.20 (3H, m), 8.11e7.98
(3H, m), 7.82 (3H, m), 7.71e7.35 (15H, m), 7.23 (1H, m), 7.19
(1H, s), 7.12 (1H, m), 7.08 (1H, s), 7.00 (1H, s), 6.97 (1H, s),
6.92 (1H, s), 6.60 (1H, s), 6.43 (1H, d, J ¼ 3.0), 4.65 (1H, m),
4.16 (4H, m), 3.98e3.55 (108H, m), 3.47e3.40 (32H, m),
3.30e3.26 (6H, m), 3.17 (2H, m). HRMS (ESþ): m/z calcd for
C152H193N17O42S8 [MþH]þ 3187.1410 found 3187.1431.
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